共 50 条
- [21] Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)Fakih, MarwanSandhu, Jaideep SinghOuyang, ChingSokol, EthanRoss, Jeffrey S.Miller, Vincent A.Lim, DeanChao, JosephCatenacci, Daniel V. T.Cho, May ThetBraiteh, Fadi S.Maron, Steven BradChase, LeahKlempner, Samuel JacobAli, Siraj MahamedSchrock, Alexa Betzig
- [22] REAL WORLD OUTCOMES IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS WHO ARE IMMUNO-ONCOLOGY (IO) NAIVE AND RECEIVED SECOND-LINE THERAPY: ANALYSIS BY TUMOR MUTATIONAL BURDEN (TMB) STATUSVALUE IN HEALTH, 2022, 25 (12) : S470 - S470Gogate, A.Palaia, J.Zhang, Y.You, M.Sama, A.
- [23] Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Spigel, David R.Schrock, Alexa BetzigFabrizio, DavidFrampton, Garrett MichaelSun, JamesHe, JieGowen, KyleJohnson, Melissa LynneBauer, Todd MichaelKalemkerian, Gregory PeterRaez, Luis E.Ou, Sai-Hong IgnatiusRoss, Jeffrey S.Stephens, Philip J.Miller, Vincent A.Ali, Siraj Mahamed
- [24] Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonistsCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 130 : 13 - 26Stein, AlexanderMoehler, MarkusTrojan, JoergGoekkurt, ErayVogel, Arndt
- [26] Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies.JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)Shah, Neil J.Ravilla, RahulOsterland, Andrew J.Todoroff, KarenWang, Ching-YuRane, PratikSaal, HakimWang, DingMotzer, Robert J.
- [27] Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in VenezuelaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Borga, GuillermoSucre, SantiagoSucre, OscarVivas, LiliamSalazar, HectorEduardo Sucre, Carlos
- [28] Tumor mutational burden (TMB) and genomic predictors of clinical outcomes to PD-1/PD-L1 checkpoint blockade in high-grade gliomasJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Iorgulescu, BryanTouat, MehdiLi, YvonneSpurr, LiamGrant, GarethPisano, WilliamLim-Fat, Mary JaneLee, EudociaNayak, LakshmiChiocca, E.Huang, RaymondCherniack, AndrewWen, PatrickIdbaih, AhmedBielle, FranckReardon, DavidLigon, Keith
- [29] Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Seeber, AndreasPuccini, AlbertoXiu, JoanneGoldberg, Richard M.Grothey, AxelShields, Anthony FrankSalem, Mohamed E.Battaglin, FrancescaEl-Deiry, Wafik S.Tokunaga, RyumaPhilip, Philip AgopMarshall, JohnKocher, FlorianHall, Michael J.Korn, Wolfgang MichaelLenz, Heinz-JosefSpizzo, Gilbert
- [30] Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-OncologyMOLECULES, 2019, 24 (06)Lee, Hyun TaeLee, Sang HyungHeo, Yong-Seok